A. Tanaka, H. Nishikawa, Shinsuke Noguchi, D. Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, D. Ha, Naoya Shigeta, T. Kitawaki, Y. Maeda, Takuro Saito, Yoshinori Shinohara, Y. Kameoka, K. Iwaisako, F. Monma, K. Ohishi, J. Karbach, E. Jäger, K. Sawada, N. Katayama, N. Takahashi, S. Sakaguchi
{"title":"酪氨酸激酶抑制剂伊马替尼通过消耗效应调节性T细胞增强肿瘤免疫","authors":"A. Tanaka, H. Nishikawa, Shinsuke Noguchi, D. Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, D. Ha, Naoya Shigeta, T. Kitawaki, Y. Maeda, Takuro Saito, Yoshinori Shinohara, Y. Kameoka, K. Iwaisako, F. Monma, K. Ohishi, J. Karbach, E. Jäger, K. Sawada, N. Katayama, N. Takahashi, S. Sakaguchi","doi":"10.1084/jem.20191009","DOIUrl":null,"url":null,"abstract":"As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers.","PeriodicalId":23015,"journal":{"name":"The Tokushima journal of experimental medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"58","resultStr":"{\"title\":\"Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells\",\"authors\":\"A. Tanaka, H. Nishikawa, Shinsuke Noguchi, D. Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, D. Ha, Naoya Shigeta, T. Kitawaki, Y. Maeda, Takuro Saito, Yoshinori Shinohara, Y. Kameoka, K. Iwaisako, F. Monma, K. Ohishi, J. Karbach, E. Jäger, K. Sawada, N. Katayama, N. Takahashi, S. Sakaguchi\",\"doi\":\"10.1084/jem.20191009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers.\",\"PeriodicalId\":23015,\"journal\":{\"name\":\"The Tokushima journal of experimental medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"58\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Tokushima journal of experimental medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1084/jem.20191009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Tokushima journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1084/jem.20191009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
As a novel type of anticancer reagent, imatinib inhibits not only BCR-ABL oncogenic protein but also LCK in T cells as an off-target, being able to selectively deplete mature T reg cells and thereby evoke effective immune responses to various cancers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
